Evidence map›Paper›PMID 32770239›Full record

ReviewThe Journal of clinical endocrinology and metabolism2020

Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.

Loes M E Moolhuijsen, Jenny A Visser

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 298 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
298citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05297058 completednot on this mapstarted 2022, after this paper: background citation

Association of Chronological Age, Subjective Age, Epigenetic Age and Bio-functional Age With Serum Anti-müllerian Hormone

TypeobservationalSponsorInsel Gruppe AG, University Hospital BernRan2022 to 2024Enrolled50ConditionsAging
NCT06999291 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of Ovarian Reserve in Critically Ill Patients Followed in the Intensive Care Unit

TypeobservationalSponsorHaseki Training and Research HospitalRan2025 to 2025Enrolled75ConditionsAnti-Mullerian Hormone DeficiencyArmsGlaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)
3 · Its place in the literature

Who cites it

298 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Evaluation of angiopoietin-like protein 4 levels in patients with endometriosis.Journal of the Turkish German Gynecological Association · 2026
    Article
  17. Role of hormone testing in assessment of infertility.Canadian family physician Medecin de famille canadien · 2026
    Article
  18. Ovarian ageing: from biological constraint to emerging therapeutic frontier.Journal of assisted reproduction and genetics · 2026
    Review
  19. Article
  20. Article

238 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Loes M E MoolhuijsenDepartment of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jenny A VisserDepartment of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextAnti-müllerian hormone (AMH) is produced by granulosa cells of small, growing follicles in the ovary. Serum AMH levels strongly correlate with the number of growing follicles, and therefore AMH has received increasing attention as a marker for ovarian reserve. This review summarizes recent findings and limitations in the application of serum AMH in ovarian reserve assessment. EVIDENCE ACQUISITION: A PubMed search was conducted to find recent literature on the measurements and use of serum AMH as a marker for ovarian reserve. EVIDENCE SYNTHESIS: Serum AMH levels are measured to assess the "functional ovarian reserve," a term that is preferred over "ovarian reserve," since AMH levels reflect the pool of growing follicles that potentially can ovulate. Serum AMH levels are used in individualized follicle-stimulating hormone dosing protocols and may predict the risk of poor response or ovarian hyperstimulation syndrome but has limited value in predicting ongoing pregnancy. Serum AMH levels are studied to predict natural or disease-related age of menopause. Studies show that the age-dependent decline rates of AMH vary among women. The generalized implementation of serum AMH measurement has also led to an increase in diagnostic assays, including automated assays. However, direct comparison of results remains problematic.

conclusionSerum AMH remains the preferred ovarian reserve marker. However, the lack of an international standard for AMH limits comparison between AMH assays. Furthermore, little is known about endogenous and exogenous factors that influence serum AMH levels, which limits proper interpretation of AMH values in a clinical setting.

Indexed as

AgingAnti-Mullerian HormoneFemaleFertilityHumansInfertility, FemaleOvarian ReserveAnti-Mullerian HormoneAMHAMH assaysfertility predictionfunctional ovarian reservemenopauseovarian reserve

Identifiers

PMID32770239
PMCPMC7486884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.